Given these promising prognostic capabilities, further basic and translational studies are needed to elucidate GDF15’s biological mechanisms in PAD pathogenesis and to assess its potential as a therapeutic target for reducing adverse limb events. The gene discussed is GDF15; the disease is peripheral arterial disease.